RS20050522A - Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation - Google Patents
Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiationInfo
- Publication number
- RS20050522A RS20050522A YUP-2005/0522A YUP20050522A RS20050522A RS 20050522 A RS20050522 A RS 20050522A YU P20050522 A YUP20050522 A YU P20050522A RS 20050522 A RS20050522 A RS 20050522A
- Authority
- RS
- Serbia
- Prior art keywords
- protein kinase
- therapeutic radiation
- effects
- increase
- tricyclic compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Triciklična jedinjenja koja inhibiraju protein kinazu kao što je CHK-1, sa sledećom formulom (gde su R2, R3 i R4 kao što je odredjeno u specifikaciji) Farmaceutske kompozicije koje sadrže efikasne količine pomenutih jedinjenja ili njihovih soli, korisne su kao pojedinačni agens ili u kombinaciji sa antineoplastičnim agensom ili terapeutskim zračenjem koje ima anti-neoplastični efekat, za lečenje bolesti ili stanja kao što su kanceri.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43939603P | 2003-01-09 | 2003-01-09 | |
PCT/IB2004/000026 WO2004063198A1 (en) | 2003-01-09 | 2004-01-05 | Diazepinoindole derivatives as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
RS20050522A true RS20050522A (en) | 2007-12-31 |
Family
ID=32713475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YUP-2005/0522A RS20050522A (en) | 2003-01-09 | 2004-01-05 | Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation |
Country Status (35)
Country | Link |
---|---|
US (3) | US6967198B2 (sr) |
EP (2) | EP1585749B1 (sr) |
JP (1) | JP3990718B2 (sr) |
KR (1) | KR100697746B1 (sr) |
CN (1) | CN1759118B (sr) |
AP (1) | AP2048A (sr) |
AT (1) | ATE404564T1 (sr) |
AU (1) | AU2004203977B2 (sr) |
BR (1) | BRPI0406701A (sr) |
CA (1) | CA2512683C (sr) |
CR (1) | CR7899A (sr) |
CY (1) | CY1108408T1 (sr) |
DE (1) | DE602004015724D1 (sr) |
DK (1) | DK1585749T3 (sr) |
EA (1) | EA009337B1 (sr) |
EC (1) | ECSP055911A (sr) |
ES (1) | ES2309484T3 (sr) |
GE (1) | GEP20084367B (sr) |
HK (1) | HK1086257A1 (sr) |
HR (1) | HRP20050624A2 (sr) |
IL (1) | IL169082A (sr) |
IS (1) | IS7884A (sr) |
MA (1) | MA27703A1 (sr) |
MX (1) | MXPA05007352A (sr) |
NO (1) | NO20053775L (sr) |
NZ (1) | NZ540638A (sr) |
OA (1) | OA13017A (sr) |
PL (1) | PL378372A1 (sr) |
PT (1) | PT1585749E (sr) |
RS (1) | RS20050522A (sr) |
SI (1) | SI1585749T1 (sr) |
TN (1) | TNSN05176A1 (sr) |
UA (1) | UA80733C2 (sr) |
WO (1) | WO2004063198A1 (sr) |
ZA (1) | ZA200504674B (sr) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1467730A4 (en) * | 2002-01-22 | 2010-03-10 | Univ California | Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof |
ES2309484T3 (es) * | 2003-01-09 | 2008-12-16 | Pfizer Inc. | Derivados de diazepinoindol como inhibidores de quinasa. |
SI1853721T1 (sl) * | 2005-02-18 | 2010-06-30 | Astrazeneca Ab | Postopek za ugotavljanje odzivnosti na CHK inhibitorje |
NZ561458A (en) | 2005-03-29 | 2011-03-31 | Icos Corp | Heteroaryl urea derivatives useful for inhibiting CHK1 |
GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US8003625B2 (en) | 2005-06-29 | 2011-08-23 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
WO2007022273A2 (en) | 2005-08-15 | 2007-02-22 | The Regents Of The University Of California | Vegf-activated fas ligands |
JP4935675B2 (ja) | 2005-08-25 | 2012-05-23 | 宇部興産株式会社 | 光学活性(S又はR)−α−アミノ酸及び光学活性(R又はS)−α−アミノ酸エステルの製造方法 |
US7645885B2 (en) * | 2005-08-26 | 2010-01-12 | The Regents Of The University Of California | Non-steroidal antiandrogens |
EP2004655A1 (en) * | 2006-04-04 | 2008-12-24 | Pfizer Products Incorporated | Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4 l)-1-oxo-2,6-dihydro-1h-ý1,2¨diazepinoý4,5,6-cd¨indol-8-yl)acetamide |
CA2648371A1 (en) * | 2006-04-04 | 2007-10-11 | Pfizer Products Inc. | Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide |
JP2010510222A (ja) * | 2006-11-17 | 2010-04-02 | シェーリング コーポレイション | 増殖性障害に対する併用療法 |
US8158656B2 (en) * | 2008-05-16 | 2012-04-17 | Shenzhen Chipscreen Biosciences Ltd. | 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
WO2010016005A1 (en) * | 2008-08-06 | 2010-02-11 | Pfizer Inc. | 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors |
WO2010040527A1 (en) * | 2008-10-10 | 2010-04-15 | Priaxon Ag | Novel compounds which modulate kinase activity |
US8314108B2 (en) | 2008-12-17 | 2012-11-20 | Eli Lilly And Company | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts |
US8663210B2 (en) | 2009-05-13 | 2014-03-04 | Novian Health, Inc. | Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy |
US8211901B2 (en) | 2009-05-22 | 2012-07-03 | Shenzhen Chipscreen Biosciences Ltd. | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
CN101906076B (zh) | 2009-06-04 | 2013-03-13 | 深圳微芯生物科技有限责任公司 | 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用 |
US9187494B2 (en) | 2011-05-06 | 2015-11-17 | Zafgen, Inc. | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators |
EP2793882A4 (en) | 2011-12-22 | 2015-04-29 | Threshold Pharmaceuticals Inc | ADMINISTRATION OF HYPOXIA ACTIVATED DRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER |
PT2797921T (pt) * | 2011-12-31 | 2017-11-14 | Beigene Ltd | Dihidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp |
CN106083849A (zh) | 2011-12-31 | 2016-11-09 | 百济神州有限公司 | 作为parp抑制剂的稠合的四元或五元环吡啶并酞嗪酮类化合物 |
CN102746211B (zh) * | 2012-06-27 | 2015-05-27 | 上海泰坦化学有限公司 | 一种取代吲哚-3-甲醛类化合物的制备方法 |
TWI633107B (zh) * | 2013-05-22 | 2018-08-21 | 開曼群島商百濟神州生物科技有限公司 | 作為parp抑制劑的稠合四或五環二氫二氮呯并咔唑酮 |
KR20160099081A (ko) | 2013-07-26 | 2016-08-19 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조합 방법 |
US10071109B2 (en) | 2013-11-06 | 2018-09-11 | Molecular Templates, Inc. | Predictive biomarker for hypoxia-activated prodrug therapy |
ES2733847T3 (es) | 2014-06-17 | 2019-12-03 | Vertex Pharma | Método para tratar cáncer usando una combinación de inhibidores de CHK1 y ATR |
KR20180041748A (ko) * | 2015-08-25 | 2018-04-24 | 베이진 엘티디 | Parp 억제제, 결정형의 제조방법 및 이의 용도 |
WO2017059357A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
CN110087730B (zh) | 2016-09-27 | 2023-03-28 | 百济神州(苏州)生物科技有限公司 | 使用包含parp抑制剂的组合产品治疗癌症 |
JP6541635B2 (ja) * | 2016-10-28 | 2019-07-10 | ベイジーン リミテッド | Parp阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン |
US10899763B2 (en) | 2017-02-28 | 2021-01-26 | Beigene, Ltd. | Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof |
US11661581B2 (en) * | 2017-05-25 | 2023-05-30 | University Of Massachusetts | Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells |
CN111108105B (zh) * | 2017-09-22 | 2023-03-31 | 朱比兰特埃皮帕德有限公司 | 作为pad抑制剂的杂环化合物 |
EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
CN113631179A (zh) * | 2019-01-25 | 2021-11-09 | 努梅迪公司 | 用于治疗特发性肺纤维化的方法 |
CN114072410B (zh) * | 2019-08-01 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 作为parp抑制剂吲哚并七元酰肟化合物 |
CN114746413B (zh) | 2019-11-29 | 2024-02-23 | 南京明德新药研发有限公司 | 二氮杂吲哚类衍生物及其作为Chk1抑制剂的应用 |
CA3184988A1 (en) * | 2020-07-13 | 2022-01-20 | Ahmed Mamai | Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof |
AU2021318572A1 (en) * | 2020-07-31 | 2023-02-16 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Indolo heptamyl oxime analog crystal as PARP inhibitor and method for preparing same |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9722320D0 (en) | 1997-10-22 | 1997-12-17 | Janssen Pharmaceutica Nv | Human cell cycle checkpoint proteins |
US6383744B1 (en) | 1998-07-10 | 2002-05-07 | Incyte Genomics, Inc. | Human checkpoint kinase |
JP2002526450A (ja) | 1998-09-18 | 2002-08-20 | スミスクライン・ビーチャム・コーポレイション | Chk1キナーゼ阻害物質 |
HU229875B1 (en) | 1999-01-11 | 2014-11-28 | Agouron Pharmaceuticals Inc La Jolla | Tricyclic inhibitors of poly(adp-ribose) polymerases |
ATE388226T1 (de) | 1999-08-27 | 2008-03-15 | Novartis Vaccines & Diagnostic | Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon |
ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
US6670167B1 (en) | 1999-11-01 | 2003-12-30 | Agouron Pharmaceuticals, Inc. | Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof |
ES2239037T3 (es) | 1999-09-22 | 2005-09-16 | Canbas Co., Ltd. | Metodos y composiciones para inhibir la deteccion del ciclo celular en g2 y sensibilizar celulas a agentes dañinos del dna. |
US6211164B1 (en) | 2000-03-10 | 2001-04-03 | Abbott Laboratories | Antisense oligonucleotides of the human chk1 gene and uses thereof |
JP4323802B2 (ja) * | 2000-12-01 | 2009-09-02 | エムジーアイ・ジーピー・インコーポレーテッド | 化合物およびその使用 |
UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
ES2309484T3 (es) * | 2003-01-09 | 2008-12-16 | Pfizer Inc. | Derivados de diazepinoindol como inhibidores de quinasa. |
-
2004
- 2004-01-05 ES ES04700145T patent/ES2309484T3/es not_active Expired - Lifetime
- 2004-01-05 CA CA2512683A patent/CA2512683C/en not_active Expired - Fee Related
- 2004-01-05 EP EP04700145A patent/EP1585749B1/en not_active Expired - Lifetime
- 2004-01-05 RS YUP-2005/0522A patent/RS20050522A/sr unknown
- 2004-01-05 DK DK04700145T patent/DK1585749T3/da active
- 2004-01-05 EA EA200500893A patent/EA009337B1/ru not_active IP Right Cessation
- 2004-01-05 NZ NZ540638A patent/NZ540638A/en unknown
- 2004-01-05 JP JP2006500278A patent/JP3990718B2/ja not_active Expired - Fee Related
- 2004-01-05 OA OA1200500197A patent/OA13017A/en unknown
- 2004-01-05 SI SI200430830T patent/SI1585749T1/sl unknown
- 2004-01-05 KR KR1020057012806A patent/KR100697746B1/ko not_active IP Right Cessation
- 2004-01-05 PL PL378372A patent/PL378372A1/pl not_active Application Discontinuation
- 2004-01-05 AT AT04700145T patent/ATE404564T1/de not_active IP Right Cessation
- 2004-01-05 MX MXPA05007352A patent/MXPA05007352A/es active IP Right Grant
- 2004-01-05 EP EP08155745A patent/EP1947102A1/en not_active Withdrawn
- 2004-01-05 GE GEAP20048886A patent/GEP20084367B/en unknown
- 2004-01-05 PT PT04700145T patent/PT1585749E/pt unknown
- 2004-01-05 CN CN2004800063838A patent/CN1759118B/zh not_active Expired - Fee Related
- 2004-01-05 AP AP2005003353A patent/AP2048A/xx active
- 2004-01-05 DE DE602004015724T patent/DE602004015724D1/de not_active Expired - Lifetime
- 2004-01-05 BR BR0406701-0A patent/BRPI0406701A/pt not_active IP Right Cessation
- 2004-01-05 WO PCT/IB2004/000026 patent/WO2004063198A1/en active IP Right Grant
- 2004-01-05 AU AU2004203977A patent/AU2004203977B2/en not_active Ceased
- 2004-01-09 US US10/754,171 patent/US6967198B2/en not_active Expired - Fee Related
- 2004-05-01 UA UAA200506730A patent/UA80733C2/uk unknown
-
2005
- 2005-06-08 ZA ZA200504674A patent/ZA200504674B/en unknown
- 2005-06-08 IL IL169082A patent/IL169082A/en not_active IP Right Cessation
- 2005-06-09 IS IS7884A patent/IS7884A/is unknown
- 2005-07-07 HR HR20050624A patent/HRP20050624A2/hr not_active Application Discontinuation
- 2005-07-08 CR CR7899A patent/CR7899A/es unknown
- 2005-07-08 TN TNP2005000176A patent/TNSN05176A1/fr unknown
- 2005-07-08 EC EC2005005911A patent/ECSP055911A/es unknown
- 2005-07-08 MA MA28375A patent/MA27703A1/fr unknown
- 2005-07-22 US US11/187,089 patent/US7132533B2/en not_active Expired - Fee Related
- 2005-08-08 NO NO20053775A patent/NO20053775L/no unknown
-
2006
- 2006-05-26 HK HK06106153.4A patent/HK1086257A1/xx not_active IP Right Cessation
- 2006-06-23 US US11/426,132 patent/US7462713B2/en not_active Expired - Fee Related
-
2008
- 2008-10-13 CY CY20081101127T patent/CY1108408T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS20050522A (en) | Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation | |
TW200635923A (en) | Tricyclic heterocycles, their manufacture and use as pharmaceutical agents | |
BRPI0507644A (pt) | pirazolopirimidinas como inibidores de cinase dependente de ciclina | |
CY1112084T1 (el) | Παραγωγα 5-φαινυλθειαζολης και χρηση ως αναστολεις της κινασης ρi3 | |
BRPI0407834A (pt) | composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase | |
MX2009005011A (es) | Imidazopirazinas como inhibidores de proteina quinasa. | |
BR0315912A (pt) | Compostos pirimìdicos com atividade antiproliferativa (ii) | |
MXPA05013142A (es) | Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer. | |
HUP0303271A2 (hu) | Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására | |
PT1678166E (pt) | Inibidores de proteína-quinase | |
MY141739A (en) | Substituted quinazoline derivatives as inhibitors of aurora kinases | |
MX2007013624A (es) | Inhibidores de proteina cinasa. | |
MXPA04002042A (es) | Compuestos de bencimidazol sustituidos y su uso para el tratamiento del cancer. | |
ATE507218T1 (de) | Benzodiazepin-derivate als rock-kinasen hemmer | |
IL197513A0 (en) | Pyrazolopyrimidine derivatives and pharmaceutical compositions containing the same | |
TW200719899A (en) | Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents | |
TW200510384A (en) | Novel farnesyl protein transferase inhibitors as antitumor agents | |
BR0116123A (pt) | Carbazóis antitumorais | |
TW200730177A (en) | 4 anilino-3-quinolinecarbonitriles for the treatment of cancer | |
TW200738680A (en) | Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents | |
TW200602329A (en) | Novel diazine derivatives, their manufacture and use as pharmaceutical agents | |
WO2003080624A3 (en) | Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases | |
PL1684763T3 (pl) | 6-arylo-7-halogeno-imidazo[1,2-a]pirymidyny jako środki przeciwnowotworowe | |
TW200626589A (en) | Azole derivatives, their manufacture and use as pharmaceutical agents | |
PT1551850E (pt) | 2 oxo-voruscharina e seus derivados |